Chipscreen(SH:688321) Zheng Quan Shi Bao Wang·2025-10-03 02:01Core Insights - Microchip Biotech has successfully established an integrated technology platform combining "AI-assisted design + chemical genomics," enabling a full process from basic research to clinical transformation [1] - The company has achieved global market approval for two innovative drugs across multiple indications and has seven products in clinical stages [1] Drug Development - The drug Sidalbenamide (Aipushai), the world's first subtype-selective HDAC oral inhibitor, has expanded its indications from peripheral T-cell lymphoma to breast cancer, adult T-cell leukemia, and diffuse large B-cell lymphoma since its approval in 2014, becoming a benchmark in the field of epigenetic therapy [1] - Siglecatin (Shuangluoping), the world's first PPAR pan-agonist, has been approved for the treatment of type 2 diabetes and included in medical insurance, showing significant potential in treating fatty liver disease [1] Clinical Pipeline - The drug Xioroni, a globally patented triple-pathway tumor-targeting inhibitor, has demonstrated good efficacy and safety in treating difficult tumors such as ovarian and pancreatic cancer [1] - Key projects such as CS23546, CS231295, and CS32582 are continuously advancing in the clinical pipeline [1] Future Prospects - The company has a pipeline of candidates with First-in-Class (FIC) and Best-in-Class (BIC) potential, including CS08399 (potential BIC brain-penetrating PRMT5 inhibitor), CS1011 (fibrosis disease inhibitor), CDCS04 (FIC molecule targeting the Alzheimer's-related ApoE4 gene), and CDCS28 (non-incretin weight loss small molecule), which are expected to become core value drivers in the future [1]